Guest Editorial Directing the narrative of your survival: How The Remission Film Festival centers survivorship stories April 24, 2026Vol.52 No.16By Edward Miskie
Guest Editorial Forty years after Chernobyl: Little evidence to show that radiation released from the accident increased cancers globally April 24, 2026Vol.52 No.16By Robert Peter Gale
Guest Editorial Most Favored Nation drug pricing could put China on top April 17, 2026Vol.52 No.15By John Stanford
Guest Editorial America needs a new blueprint for the National Cancer ProgramFirst step: Develop Version 2.0 of Paul Calabresi’s “Cancer at a Crossroads” April 10, 2026Vol.52 No.14By Robert A. Winn
FreeGuest Editorial FDA’s guidance on MRD in MM goes beyond the ODAC vote—and that’s where it matters mostDraft guidance consolidates trial design updates for developers April 03, 2026Vol.52 No.13By Nicholas Richardson
Guest Editorial As more people are surviving cancer, we must continue funding bold science March 13, 2026Vol.52 No.10By Karen E. Knudsen
Guest Editorial When radiology fails to fix clinical trial imaging workflow at sites…What most think, why it’s wrong, and what cancer centers really need February 27, 2026Vol.52 No.08By Jeff Sorenson
Guest Editorial Sustaining community oncology through nonprofit structures and shared technology infrastructure February 20, 2026Vol.52 No.07By Jacob Welkley
Guest Editorial California Institute of Regenerative Medicine and Cancer Research: A promise broken? February 20, 2026Vol.52 No.07By Stephen J. Forman
FreeGuest Editorial Science is winning the war on cancer—CMS shouldn’t disarm February 13, 2026Vol.52 No.06By John M. O’Brien
